KRTL Holding merges with Bolivia’s Sigma Pharma to expand cross-border biotech operations

In a strategic move aimed at expanding its footprint across the Americas, KRTL Holding Group Inc. (OTC: KRTL) has announced the completion of a cross-border merger between its wholly owned subsidiary, KRTL Biotech, Inc., and Bolivian pharmaceutical manufacturer Industria Químico Farmacéutica Sigma Corp. S.R.L. The transaction, finalized via a share and quotas exchange agreement on September 2, 2025, marks a pivotal milestone in KRTL’s international growth strategy.

The structure of the merger grants KRTL Biotech 99% ownership of Sigma’s capital quotas. In return, KRTL Biotech has issued 490 million common shares—representing 49% of its total equity—to the Wilstermann family, the former full owners of Sigma. The deal includes a preferred share issued to Patricia Wilstermann, ensuring a permanent board seat at the KRTL Holding level, symbolizing both governance continuity and a balance of power in this binational alliance.

But beyond the ownership math lies a more interesting question: Why does a U.S.-based biotech firm want deep operational roots in Bolivia—and how does that change the nature of pharmaceutical trade in the region?

How does the KRTL–Sigma merger support pharmaceutical manufacturing and drug exports across borders?

At its core, this merger is not about market capture—it’s about production scalability, compliance integration, and unlocking bilateral pharma trade between Latin America and the U.S. The combined entity aims to use Sigma’s well-established Bolivian manufacturing base to produce compliant drugs and nutraceuticals for export into the U.S. market. Conversely, KRTL’s U.S.-based compliance and regulatory expertise will help commercialize American therapeutics across Latin America using Sigma’s local distribution infrastructure.

This two-way drug pipeline is made possible by Sigma’s extensive licensing and production capabilities in Bolivia, which KRTL can now consolidate under U.S. accounting standards (ASC 810) for financial reporting. That means Sigma’s operations, though functionally autonomous, will contribute directly to KRTL Biotech’s topline figures.

Such vertical integration could offer a scalable solution for companies seeking FDA-quality standards without the higher costs associated with U.S.-only production. Dan Bishop, CEO of KRTL Biotech, stressed that the merger allows the company to “better serve international markets while maintaining the highest quality standards.”

What’s the backstory behind KRTL and Sigma—and how did the merger come about?

The foundations for this merger were laid earlier this year when KRTL Biotech signed a Memorandum of Understanding (MOU) with Sigma in March 2025. The MOU laid out several key elements, including a shared governance model, cross-border compliance alignment, and consolidation of revenue streams through a U.S.-based financial entity called SIGMARTL Corp.

At that stage, KRTL’s aim was clear: to create a regulatory and commercial bridge between U.S.-compliant drug development and scalable South American manufacturing. Sigma, for its part, welcomed the MOU as a way to scale its 40%-utilized production facilities and expand into U.S. markets.

Patricia Wilstermann, CEO of Sigma, emphasized that the full merger preserves her team’s operational control in Bolivia while opening new doors globally. Her board seat at KRTL Holding was not just a governance gesture—it was a strategic design to prevent cultural or managerial erosion during the integration process.

What are the financial implications of the merger for KRTL Holding Group and its investors?

While KRTL Holding Group has not disclosed a cash valuation for the deal, the issuance of 490 million shares in KRTL Biotech for a 99% stake in Sigma implies a significant equity-based transfer of control. However, the long-term reward may lie in the financial consolidation benefits.

Sigma’s current annual revenues exceed $20 million, with the potential to double within two years post-integration, assuming full utilization of its production facilities.

That could significantly boost KRTL Biotech’s top-line numbers—and by extension, enhance investor sentiment around KRTL Holding’s OTC stock. With Sigma’s results now folded into KRTL’s GAAP reporting structure, investors will be able to evaluate a more robust, revenue-generating business model with clearer international exposure.

Moreover, the consolidation provides KRTL Holding with improved capital allocation visibility, shared cost efficiencies, and vertically integrated supply chain advantages.

How does this position KRTL Biotech in the broader pharmaceutical and biotech landscape?

For a company that’s still flying under the radar in the U.S. public markets, this merger is a bold play. Unlike traditional biotech firms that focus exclusively on early-stage research, KRTL Biotech appears to be building a hybrid business model: part regulatory compliance engine, part international commercialization hub.

The deal supports a broader trend in biopharmaceuticals where mid-cap and emerging players are looking beyond domestic borders for competitive advantage—not just in R&D but also in cost-effective manufacturing, local regulatory penetration, and faster go-to-market channels.

In that sense, KRTL Biotech is aligning itself more closely with companies that play the “global arbitrage” game in life sciences—leveraging cost-efficient emerging markets while maintaining first-world compliance for credibility and scale.

What could investors expect next as integration begins across the Americas?

The merger sets the stage for a series of next steps. These include full-scale financial integration of SIGMA into KRTL Biotech, ramp-up of production at SIGMA’s Bolivian facilities, and FDA-aligned quality checks for U.S. market entry. Future M&A activity or product launches could be expected, especially now that KRTL has access to regional production capacity and existing market licenses in Bolivia and neighboring countries.

The forward-looking statements in KRTL’s own press releases hint at broader ambitions in public health innovation, nutraceuticals, and clinical-grade exports. If the integration plays out as intended, KRTL may quickly evolve from a niche biotech name into a credible mid-cap pharma enabler with Latin American muscle and U.S. market reach.

How is the stock market reacting to KRTL’s bold move—and what’s the sentiment outlook?

While KRTL Holding Group (OTC: KRTL) trades on the over-the-counter market with relatively low volume, investor attention may pick up following this transaction, especially from microcap-focused funds and Latin America-centric pharma investors. There is no immediate spike in trading volume or price reported post-merger, but this deal could represent a medium-term re-rating opportunity, contingent on KRTL’s execution.

Institutional interest is likely to remain muted in the short term until audited post-merger financials show traction. However, if KRTL can demonstrate margin expansion and revenue scaling from Sigma’s now-majority-owned assets, buy-side sentiment may shift toward a more bullish tone. Until then, this merger represents a speculative but potentially high-upside narrative for long-horizon investors.

Can KRTL Biotech become a poster child for binational biotech strategy?

With this merger, KRTL isn’t just expanding—it’s redefining what cross-border biotech collaboration can look like. By embedding Bolivian manufacturing into a U.S. compliance-first shell, the company is attempting to flip the traditional outsourcing model on its head. Instead of offshore-only production for cost savings, it’s building a two-way trade lane of innovation, manufacturing, and compliance across hemispheres.

If successful, KRTL Biotech could offer a blueprint for emerging life sciences firms seeking scalable growth outside traditional R&D pipelines—especially in an era when global supply chains, regulatory localization, and health sovereignty are reshaping pharmaceutical strategies.

Whether the market rewards that blueprint will depend on how well KRTL balances execution with expansion. But one thing is clear: this isn’t just a merger—it’s a statement of intent.